Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 95 от 222

Recruiting Phase 2

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Obesity/Overweight

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

Начало: 20.05.2025 Край: 06.08.2026 Възраст: 18–55 г.

China AstraZeneca NCT07017179

Recruiting Phase 4

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Начало: 20.05.2025 Край: 01.12.2032 Възраст: от 18 г. Treatment

Australia, France, Italy +5 Eli Lilly and Company NCT06876649

Recruiting Phase 4

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Начало: 20.05.2025 Край: 01.12.2032 Възраст: от 18 г. Treatment

Australia, France, Italy +5 Eli Lilly and Company NCT06876662

Recruiting Phase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Delayed Graft Function DGF Kidney Transplant

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Начало: 19.05.2025 Край: 06.11.2028 Възраст: от 18 г. Treatment

Argentina, Australia, Brazil +13 Alexion Pharmaceuticals, Inc. NCT06830798

Recruiting

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

Lower Extremity Acute Limb Ischemia LE ALI

The primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the Indigo™ Aspiration System in a patient population with lower extremity acute limb ischemia (LE ALI).

Начало: 18.05.2025 Край: 01.01.2029 Възраст: от 18 г.

Australia, Germany, Italy +2 Penumbra Inc. NCT06747117

Recruiting

Validity of ICU Clinician's Appraisal of Proportionality in CPR

Cardiac Arrest, Out-Of-Hospital

The VICAP-CPR study investigates whether doctors and nurses working in Intensive Care can determine neurological outcome and future quality of life after six months in patients treated for cardiac arrest outside the hospital based on clinical assessment in the first 24 hours after admission to Intensive Care. To conduct this study, the results of the questionnaire offered to Intensive Care doctors and nurses regarding the estimation of long-term neurological outcome and quality of life will be compared with the neurological outcome and quality of life as recorded in the STEPCARE study (NCT 05564754). The aim of the international STEPCARE study is to determine the best combination of post-resuscitation care to favourably influence survival and neurological outcome in patients treated for cardiac arrest outside hospital.

Начало: 18.05.2025 Край: 30.12.2026 Възраст: от 18 г.

Austria, Belgium, Finland +5 University Hospital, Ghent NCT07026773

Recruiting

High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Anxiety

Recurrent Pregnancy Loss Anxiety Disorders

This proof-of-concept trial investigates whether high-intensity, low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the right dorsolateral prefrontal cortex (DLPFC) can improve autonomic cardiac regulation in women with recurrent pregnancy loss (RPL) and anxiety. The study explores the lateralised function of the DLPFC in emotional and autonomic control and tests a novel neuromodulation-based strategy to relieve anxiety and sympathetic overactivation.

Начало: 16.05.2025 Край: 30.04.2026 Възраст: 18–45 г.

China Shenyang Jinghua Hospital NCT06968026

Recruiting Phase 2

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help more patients with the IDH2 gene get rid of AML. ASTX727 is a fixed-dose formulation of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Enasidenib works by stopping the growth and spread of tumor cells that have the IDH2 mutation. Giving ASTX727 and venetoclax plus enasidenib may work better in treating AML patients with the IDH2 mutation.

Начало: 16.05.2025 Край: 31.03.2027 Възраст: от 18 г.

Puerto Rico, United States National Cancer Institute (NCI) NCT06672146

Recruiting Phase 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Prostate Cancer Prostate Cancer Patients With Detectable PSA Following Prostatectomy Prostate Cancer Recurrent Prostate Cancer Patients Who Have Brachytherapy Seed Implant +2

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Начало: 16.05.2025 Край: 31.12.2026 Възраст: от 18 г. Diagnostic

Australia, United States Clarity Pharmaceuticals Ltd NCT06970847

Recruiting

HARP Mindfulness Study

Cardiovascular Diseases

This study was designed using the Multiphase Optimization Strategy (MOST) framework to determine whether two supplemental components increase the efficacy of a mindfulness-based cognitive therapy program delivered via telephone (MBCT-T) for psychological distress. Specifically, this study will test mindfulness booster sessions to follow a standard 8-week MBCT-T intervention, as well as website support in patients with heart disease and/or heart disease risk factors.

Начало: 15.05.2025 Край: 31.12.2026 Възраст: от 18 г.

United States NYU Langone Health NCT05841784

Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Начало: 15.05.2025 Край: 31.12.2029 Възраст: от 18 г.

Poland AstraZeneca NCT06909253

Recruiting Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder Neoplasms Immune Checkpoint Inhibitors Methotrexate Vinblastine +3

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.

Начало: 15.05.2025 Край: 31.10.2028 Възраст: от 18 г. Treatment

Australia, Brazil, Canada +4 AstraZeneca NCT06960577

Recruiting Phase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Prostate Cancer Other Solid Tumors Ewing Sarcoma

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.

Начало: 15.05.2025 Край: 01.04.2030 Възраст: 18–75 г.

China Hangzhou DAC Biotechnology Co., Ltd. NCT06926283

Recruiting

Digital Mindset Intervention for Half Marathon Performance

Healthy Exercise Psychological Intervention

The goal of this randomized controlled trial is to test whether a brief digital mindset training program can improve performance among recreational runners training for a half marathon in New Zealand in 2025. The study will recruit healthy adult participants who are registered for an upcoming half-marathon event. The study aims to answer two main questions: 1. Does the mindset training program - designed to reframe common physical symptoms like fatigue or muscle soreness as signs of progress - help more runners complete the race and improve their official times, compared to standard training advice? 2. Does it support better training (e.g., longer peak training weeks) and faster physical recovery after the race? Researchers will compare participants who receive the mindset training program to those who receive widely followed half-marathon training content and a group who receive no study content, to see whether the mindset training leads to better half-marathon performance and training outcomes. Participants will: * Complete a brief online survey at the start of the study * Receive and engage with four pieces of digital content across nine weeks before the half-marathon race (if assigned to a training group) * Complete a follow-up survey after the half-marathon

Начало: 15.05.2025 Край: 01.09.2025 Възраст: от 18 г. Supportive care

New Zealand University of Auckland, New Zealand NCT06972121

Recruiting Phase 2

Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children

Recurrent Respiratory Tract Infections

This study is an 8-weeks, randomized controlled trial involving children under 6 years of age who meet clinical diagnostic criteria for RRTI. Participants are randomized to receive either probiotic or placebo. The primary clinical outcomes assessed are duration and frequency of respiratory symptoms and quality of life. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for metagenomics gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.

Начало: 14.05.2025 Край: 30.06.2026 Възраст: 1–6 г.

China, Malaysia Min-Tze LIONG NCT07297966

Recruiting Phase 4

BoTox Into the Sternocleidomastoid Muscles (SCM)

Neck Muscle Issue

Botulinum toxin injections have been used both in the face and neck for many years. However, injection into the sternocleidomastoid muscle (SCM) has only been done to treat neck spasms. In this study botulinum toxin will be injected into the SCM to determine if this will result in a temporary slimming effect on the neck and produce a more feminine, youthful neck contour.

Начало: 14.05.2025 Край: 01.08.2026 Възраст: 18–65 г.

United States Boston Medical Center NCT06903975

Recruiting Phase 2

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.

Начало: 14.05.2025 Край: 08.06.2028 Възраст: от 18 г.

Canada, Colombia, United States Takeda NCT06798012

Recruiting Phase 1

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Head and Neck Squamous Cell Carcinoma

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site. Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 14.05.2025 Край: 31.07.2027 Възраст: от 18 г. Treatment

Australia, Brazil, Bulgaria +19 Boehringer Ingelheim NCT06806852

Recruiting

Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder

Binge-Eating Disorder

This project includes testing circadian reset technology (CRT) on frequency of binge eating in a sample of 40 individuals with binge eating disorder. Participants will be randomized to one of two groups. Both groups use a virtual reality (VR) headset for 10 minutes (5 upon waking, 5 before sleep) daily for 1 month. One group will use the CRT software on the headset and the other group will use a software intended to be a control. Measures will be taken at baseline and 1-month. The researchers anticipate that use of CRT will improve sleep quality leading to increased appetitive control.

Начало: 13.05.2025 Край: 01.11.2026 Възраст: от 18 г.

United States Icahn School of Medicine at Mount Sinai NCT06858774

Recruiting Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate Cancer Prostatic Neoplasms

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.

Начало: 13.05.2025 Край: 06.01.2031 Възраст: от 18 г. Treatment

Argentina, Australia, Austria +31 Merck Sharp & Dohme LLC NCT06925737

1 … 93 94 95 96 97 … 222